CASI Pharmaceuticals, Inc. (CASI) Set to Announce Quarterly Earnings on Monday

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is scheduled to issue its quarterly earnings data on Monday, August 14th.

CASI Pharmaceuticals (NASDAQ:CASI) last posted its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. On average, analysts expect CASI Pharmaceuticals to post $-0.13 EPS for the current fiscal year and $-0.19 EPS for the next fiscal year.

CASI Pharmaceuticals, Inc. (CASI) opened at 1.01 on Friday. The company’s market capitalization is $60.80 million. CASI Pharmaceuticals, Inc. has a 1-year low of $0.91 and a 1-year high of $1.76. The firm has a 50-day moving average price of $1.05 and a 200 day moving average price of $1.17.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://transcriptdaily.com/2017/08/13/casi-pharmaceuticals-inc-casi-set-to-announce-quarterly-earnings-on-monday.html.

A number of analysts have recently commented on CASI shares. Maxim Group set a $4.00 price objective on CASI Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, May 16th. ValuEngine upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply